CRISPR Therapeutics AG
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Samarth Kulkarni Ph.D.
- Full Time Employees
- 393
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Baarerstrasse 14 Zug Switzerland 6300
- IPO Date
- Oct 19, 2016
- CIK
- 0001674416
- Website
- crisprtx.com
- Similar Companies
- Business
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Company News
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million?
Crispr Therapeutics: Betting On A One-Shot Future
Biotech Stock for Options Bears to Target Right Now
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)
The Best Stocks to Invest $1,000 in Right Now
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
5 Monster Stocks to Hold for the Next 10 Years
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years